The proteome, or collection of proteoforms expressed in a biological system, is dynamic and
heterogeneous. As our appreciation for the complexity of the proteome has evolved, so have …

Immuno-oncology holds promise for transforming patient care having achieved durable
clinical response rates across a variety of advanced and metastatic cancers. Despite these …

Based on the success of cancer immunotherapy, personalized cancer vaccines have
emerged as a leading oncology treatment. Antigen presentation on MHC class I (MHC-I) is …

Motivation Tumor polyvalent neoantigen mRNA vaccines are gaining prominence in
immunotherapy. The design of sequences in vaccine development is crucial for enhancing …

Recombinant antibodies and, more recently, T cell receptor (TCR)-engineered T cell
therapies represent two immunological strategies that have come to the forefront of clinical …

Next-generation sequencing (NGS) has revolutionized nearly every area of biology,
allowing for exponential increases in information across genomes, transcriptomes …

Hotspot driver mutations presented by human leukocyte antigens might be recognized by
anti-tumor T cells. Based on their advantages of tumor-specificity and immunogenicity …

Efficacy of cancer immunotherapies relies on correct recognition of tumor antigens by
lymphocytes, eliciting thus functional responses capable of eliminating tumor cells …

Introduction T cells engineered to express antigen-specific T cell receptors (TCR; TCR-T)
are a promising class of immunotherapeutic for patients with hematologic malignancies. Like …

Human Leukocyte Antigen (HLA) is like a device that monitors the internal environment of
the body. T lymphocytes immediately recognize the HLA molecules that are expressed on …